nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—MSX1—stomach cancer	0.00769	0.11	CbGpPWpGaD
Lisdexamfetamine—Lacosamide—CA1—stomach cancer	0.00742	0.207	CrCbGaD
Lisdexamfetamine—Lisinopril—ACE—stomach cancer	0.00645	0.18	CrCbGaD
Lisdexamfetamine—Lacosamide—CA2—stomach cancer	0.00562	0.157	CrCbGaD
Lisdexamfetamine—Labetalol—ADRB1—stomach cancer	0.00507	0.142	CrCbGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—MSX1—stomach cancer	0.00458	0.0656	CbGpPWpGaD
Lisdexamfetamine—Labetalol—ADRB2—stomach cancer	0.00427	0.119	CrCbGaD
Lisdexamfetamine—Selegiline—CYP2A6—stomach cancer	0.0038	0.106	CrCbGaD
Lisdexamfetamine—Amphetamine—CYP2A6—stomach cancer	0.00316	0.0882	CrCbGaD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRB1—stomach cancer	0.003	0.0429	CbGpPWpGaD
Lisdexamfetamine—Affect lability—Epirubicin—stomach cancer	0.00267	0.00299	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Docetaxel—stomach cancer	0.00263	0.00294	CcSEcCtD
Lisdexamfetamine—Anorexia—Fluorouracil—stomach cancer	0.00261	0.00292	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Methotrexate—stomach cancer	0.00261	0.00292	CcSEcCtD
Lisdexamfetamine—Eye disorder—Docetaxel—stomach cancer	0.0026	0.00291	CcSEcCtD
Lisdexamfetamine—Visual impairment—Capecitabine—stomach cancer	0.0026	0.0029	CcSEcCtD
Lisdexamfetamine—Insomnia—Irinotecan—stomach cancer	0.00259	0.00289	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Docetaxel—stomach cancer	0.00258	0.00289	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—stomach cancer	0.00256	0.00287	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Irinotecan—stomach cancer	0.00255	0.00285	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Capecitabine—stomach cancer	0.00255	0.00285	CcSEcCtD
Lisdexamfetamine—Somnolence—Irinotecan—stomach cancer	0.00254	0.00284	CcSEcCtD
Lisdexamfetamine—Eye disorder—Capecitabine—stomach cancer	0.00252	0.00282	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Irinotecan—stomach cancer	0.00252	0.00282	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Docetaxel—stomach cancer	0.00251	0.00281	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—stomach cancer	0.00251	0.00281	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Docetaxel—stomach cancer	0.00251	0.00281	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Capecitabine—stomach cancer	0.0025	0.0028	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Irinotecan—stomach cancer	0.00249	0.00278	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Epirubicin—stomach cancer	0.00248	0.00277	CcSEcCtD
Lisdexamfetamine—Insomnia—Fluorouracil—stomach cancer	0.00248	0.00277	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—stomach cancer	0.00247	0.00276	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Irinotecan—stomach cancer	0.00247	0.00276	CcSEcCtD
Lisdexamfetamine—Fatigue—Irinotecan—stomach cancer	0.00247	0.00276	CcSEcCtD
Lisdexamfetamine—Constipation—Irinotecan—stomach cancer	0.00245	0.00274	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Epirubicin—stomach cancer	0.00244	0.00273	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Fluorouracil—stomach cancer	0.00244	0.00273	CcSEcCtD
Lisdexamfetamine—Mental disorder—Docetaxel—stomach cancer	0.00244	0.00273	CcSEcCtD
Lisdexamfetamine—Somnolence—Fluorouracil—stomach cancer	0.00244	0.00272	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Capecitabine—stomach cancer	0.00243	0.00272	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Capecitabine—stomach cancer	0.00243	0.00272	CcSEcCtD
Lisdexamfetamine—ADRA1B—Adrenoceptors—ADRB2—stomach cancer	0.00243	0.0348	CbGpPWpGaD
Lisdexamfetamine—Malnutrition—Docetaxel—stomach cancer	0.00242	0.00271	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Fluorouracil—stomach cancer	0.00241	0.0027	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Fluorouracil—stomach cancer	0.00238	0.00266	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.00237	0.00265	CcSEcCtD
Lisdexamfetamine—Mental disorder—Capecitabine—stomach cancer	0.00236	0.00264	CcSEcCtD
Lisdexamfetamine—Malnutrition—Capecitabine—stomach cancer	0.00235	0.00262	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Methotrexate—stomach cancer	0.00231	0.00258	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—stomach cancer	0.00229	0.00257	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Irinotecan—stomach cancer	0.00226	0.00253	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—stomach cancer	0.00226	0.00253	CcSEcCtD
Lisdexamfetamine—Depression—Methotrexate—stomach cancer	0.00223	0.00249	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Methotrexate—stomach cancer	0.00222	0.00248	CcSEcCtD
Lisdexamfetamine—Vision blurred—Capecitabine—stomach cancer	0.00221	0.00247	CcSEcCtD
Lisdexamfetamine—Tremor—Capecitabine—stomach cancer	0.0022	0.00246	CcSEcCtD
Lisdexamfetamine—Urticaria—Fluorouracil—stomach cancer	0.00218	0.00243	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Fluorouracil—stomach cancer	0.00217	0.00242	CcSEcCtD
Lisdexamfetamine—Palpitations—Docetaxel—stomach cancer	0.00214	0.00239	CcSEcCtD
Lisdexamfetamine—Weight increased—Epirubicin—stomach cancer	0.00214	0.00239	CcSEcCtD
Lisdexamfetamine—Weight decreased—Epirubicin—stomach cancer	0.00212	0.00237	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—stomach cancer	0.00211	0.00236	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Irinotecan—stomach cancer	0.00211	0.00236	CcSEcCtD
Lisdexamfetamine—Convulsion—Docetaxel—stomach cancer	0.0021	0.00235	CcSEcCtD
Lisdexamfetamine—Hypertension—Docetaxel—stomach cancer	0.00209	0.00234	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Epirubicin—stomach cancer	0.00207	0.00232	CcSEcCtD
Lisdexamfetamine—Palpitations—Capecitabine—stomach cancer	0.00207	0.00232	CcSEcCtD
Lisdexamfetamine—Asthenia—Irinotecan—stomach cancer	0.00205	0.0023	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.00205	0.00229	CcSEcCtD
Lisdexamfetamine—Hypertension—Capecitabine—stomach cancer	0.00203	0.00227	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Fluorouracil—stomach cancer	0.00202	0.00226	CcSEcCtD
Lisdexamfetamine—Dry mouth—Docetaxel—stomach cancer	0.00202	0.00226	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—stomach cancer	0.00201	0.00224	CcSEcCtD
Lisdexamfetamine—Anxiety—Capecitabine—stomach cancer	0.00199	0.00223	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.00198	0.00222	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Epirubicin—stomach cancer	0.00198	0.00221	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Docetaxel—stomach cancer	0.00198	0.00221	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—stomach cancer	0.00198	0.00221	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—stomach cancer	0.00196	0.0022	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Irinotecan—stomach cancer	0.00196	0.00219	CcSEcCtD
Lisdexamfetamine—Dry mouth—Capecitabine—stomach cancer	0.00195	0.00218	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Docetaxel—stomach cancer	0.00194	0.00217	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—stomach cancer	0.00193	0.00216	CcSEcCtD
Lisdexamfetamine—Tachycardia—Docetaxel—stomach cancer	0.00193	0.00216	CcSEcCtD
Lisdexamfetamine—Skin disorder—Docetaxel—stomach cancer	0.00192	0.00215	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—stomach cancer	0.00192	0.00215	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—stomach cancer	0.0019	0.00212	CcSEcCtD
Lisdexamfetamine—Dizziness—Irinotecan—stomach cancer	0.00189	0.00212	CcSEcCtD
Lisdexamfetamine—Anorexia—Docetaxel—stomach cancer	0.00189	0.00211	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Capecitabine—stomach cancer	0.00188	0.0021	CcSEcCtD
Lisdexamfetamine—Hepatitis—Epirubicin—stomach cancer	0.00188	0.0021	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—stomach cancer	0.00188	0.0021	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Fluorouracil—stomach cancer	0.00188	0.0021	CcSEcCtD
Lisdexamfetamine—Tachycardia—Capecitabine—stomach cancer	0.00187	0.00209	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—stomach cancer	0.00186	0.00208	CcSEcCtD
Lisdexamfetamine—Skin disorder—Capecitabine—stomach cancer	0.00186	0.00208	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Capecitabine—stomach cancer	0.00185	0.00207	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—stomach cancer	0.00183	0.00205	CcSEcCtD
Lisdexamfetamine—Anorexia—Capecitabine—stomach cancer	0.00183	0.00204	CcSEcCtD
Lisdexamfetamine—Vomiting—Irinotecan—stomach cancer	0.00182	0.00203	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—stomach cancer	0.00181	0.00203	CcSEcCtD
Lisdexamfetamine—Dizziness—Fluorouracil—stomach cancer	0.00181	0.00203	CcSEcCtD
Lisdexamfetamine—Visual impairment—Epirubicin—stomach cancer	0.00181	0.00202	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—stomach cancer	0.00181	0.00202	CcSEcCtD
Lisdexamfetamine—Rash—Irinotecan—stomach cancer	0.0018	0.00202	CcSEcCtD
Lisdexamfetamine—Dermatitis—Irinotecan—stomach cancer	0.0018	0.00202	CcSEcCtD
Lisdexamfetamine—Headache—Irinotecan—stomach cancer	0.00179	0.002	CcSEcCtD
Lisdexamfetamine—Insomnia—Docetaxel—stomach cancer	0.00179	0.002	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Epirubicin—stomach cancer	0.00178	0.00199	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Docetaxel—stomach cancer	0.00176	0.00197	CcSEcCtD
Lisdexamfetamine—Somnolence—Docetaxel—stomach cancer	0.00176	0.00197	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—stomach cancer	0.00176	0.00197	CcSEcCtD
Lisdexamfetamine—Eye disorder—Epirubicin—stomach cancer	0.00176	0.00196	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—stomach cancer	0.00175	0.00195	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Epirubicin—stomach cancer	0.00174	0.00195	CcSEcCtD
Lisdexamfetamine—Vomiting—Fluorouracil—stomach cancer	0.00174	0.00195	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Docetaxel—stomach cancer	0.00174	0.00195	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—stomach cancer	0.00174	0.00194	CcSEcCtD
Lisdexamfetamine—Insomnia—Capecitabine—stomach cancer	0.00173	0.00194	CcSEcCtD
Lisdexamfetamine—Rash—Fluorouracil—stomach cancer	0.00173	0.00193	CcSEcCtD
Lisdexamfetamine—Dermatitis—Fluorouracil—stomach cancer	0.00173	0.00193	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Docetaxel—stomach cancer	0.00172	0.00192	CcSEcCtD
Lisdexamfetamine—Headache—Fluorouracil—stomach cancer	0.00172	0.00192	CcSEcCtD
Lisdexamfetamine—SLC18A2—Neurotransmitter Release Cycle—HSPA8—stomach cancer	0.00171	0.0245	CbGpPWpGaD
Lisdexamfetamine—Gastrointestinal disorder—Docetaxel—stomach cancer	0.00171	0.00191	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Capecitabine—stomach cancer	0.00171	0.00191	CcSEcCtD
Lisdexamfetamine—Fatigue—Docetaxel—stomach cancer	0.00171	0.00191	CcSEcCtD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HRH4—stomach cancer	0.0017	0.0244	CbGpPWpGaD
Lisdexamfetamine—Nausea—Irinotecan—stomach cancer	0.0017	0.0019	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Epirubicin—stomach cancer	0.0017	0.0019	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Epirubicin—stomach cancer	0.00169	0.00189	CcSEcCtD
Lisdexamfetamine—Constipation—Docetaxel—stomach cancer	0.00169	0.00189	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Capecitabine—stomach cancer	0.00169	0.00188	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—stomach cancer	0.00167	0.00187	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Capecitabine—stomach cancer	0.00166	0.00186	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Capecitabine—stomach cancer	0.00165	0.00185	CcSEcCtD
Lisdexamfetamine—Fatigue—Capecitabine—stomach cancer	0.00165	0.00185	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—stomach cancer	0.00165	0.00184	CcSEcCtD
Lisdexamfetamine—Mental disorder—Epirubicin—stomach cancer	0.00165	0.00184	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—stomach cancer	0.00164	0.00184	CcSEcCtD
Lisdexamfetamine—Constipation—Capecitabine—stomach cancer	0.00164	0.00183	CcSEcCtD
Lisdexamfetamine—Malnutrition—Epirubicin—stomach cancer	0.00163	0.00183	CcSEcCtD
Lisdexamfetamine—Nausea—Fluorouracil—stomach cancer	0.00163	0.00182	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—stomach cancer	0.00162	0.00182	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—stomach cancer	0.00161	0.0018	CcSEcCtD
Lisdexamfetamine—Nervousness—Epirubicin—stomach cancer	0.00159	0.00178	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—stomach cancer	0.00157	0.00175	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—stomach cancer	0.00157	0.00175	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Docetaxel—stomach cancer	0.00156	0.00175	CcSEcCtD
Lisdexamfetamine—Vision blurred—Epirubicin—stomach cancer	0.00154	0.00172	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—stomach cancer	0.00152	0.0017	CcSEcCtD
Lisdexamfetamine—Urticaria—Capecitabine—stomach cancer	0.00152	0.0017	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Capecitabine—stomach cancer	0.00151	0.00169	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—stomach cancer	0.00151	0.00169	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—stomach cancer	0.00151	0.00169	CcSEcCtD
Lisdexamfetamine—Agitation—Epirubicin—stomach cancer	0.0015	0.00168	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.00148	0.00165	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—stomach cancer	0.00147	0.00164	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Docetaxel—stomach cancer	0.00146	0.00163	CcSEcCtD
Lisdexamfetamine—Palpitations—Epirubicin—stomach cancer	0.00144	0.00162	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—stomach cancer	0.00143	0.00159	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—stomach cancer	0.00143	0.00159	CcSEcCtD
Lisdexamfetamine—Asthenia—Docetaxel—stomach cancer	0.00142	0.00159	CcSEcCtD
Lisdexamfetamine—Convulsion—Epirubicin—stomach cancer	0.00142	0.00158	CcSEcCtD
Lisdexamfetamine—Hypertension—Epirubicin—stomach cancer	0.00141	0.00158	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Capecitabine—stomach cancer	0.00141	0.00158	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—stomach cancer	0.0014	0.00156	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—stomach cancer	0.00139	0.00155	CcSEcCtD
Lisdexamfetamine—Anxiety—Epirubicin—stomach cancer	0.00139	0.00155	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—stomach cancer	0.00138	0.00155	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.00138	0.00155	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—stomach cancer	0.00138	0.00154	CcSEcCtD
Lisdexamfetamine—Asthenia—Capecitabine—stomach cancer	0.00137	0.00154	CcSEcCtD
Lisdexamfetamine—Dry mouth—Epirubicin—stomach cancer	0.00136	0.00152	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—stomach cancer	0.00136	0.00152	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Docetaxel—stomach cancer	0.00135	0.00151	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—stomach cancer	0.00134	0.00149	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Epirubicin—stomach cancer	0.00133	0.00149	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—stomach cancer	0.00131	0.00147	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Capecitabine—stomach cancer	0.00131	0.00147	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Epirubicin—stomach cancer	0.00131	0.00146	CcSEcCtD
Lisdexamfetamine—Dizziness—Docetaxel—stomach cancer	0.00131	0.00146	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—stomach cancer	0.00131	0.00146	CcSEcCtD
Lisdexamfetamine—Tachycardia—Epirubicin—stomach cancer	0.0013	0.00146	CcSEcCtD
Lisdexamfetamine—Skin disorder—Epirubicin—stomach cancer	0.0013	0.00145	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Epirubicin—stomach cancer	0.00129	0.00144	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—stomach cancer	0.00129	0.00144	CcSEcCtD
Lisdexamfetamine—Anxiety—Doxorubicin—stomach cancer	0.00128	0.00143	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.00128	0.00143	CcSEcCtD
Lisdexamfetamine—Anorexia—Epirubicin—stomach cancer	0.00127	0.00142	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—stomach cancer	0.00127	0.00142	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—stomach cancer	0.00127	0.00142	CcSEcCtD
Lisdexamfetamine—Dizziness—Capecitabine—stomach cancer	0.00127	0.00142	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—stomach cancer	0.00126	0.00141	CcSEcCtD
Lisdexamfetamine—Vomiting—Docetaxel—stomach cancer	0.00126	0.00141	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—stomach cancer	0.00126	0.0014	CcSEcCtD
Lisdexamfetamine—Rash—Docetaxel—stomach cancer	0.00125	0.00139	CcSEcCtD
Lisdexamfetamine—Dermatitis—Docetaxel—stomach cancer	0.00125	0.00139	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—stomach cancer	0.00124	0.00139	CcSEcCtD
Lisdexamfetamine—Headache—Docetaxel—stomach cancer	0.00124	0.00139	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—stomach cancer	0.00123	0.00138	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—stomach cancer	0.00123	0.00138	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—stomach cancer	0.00123	0.00137	CcSEcCtD
Lisdexamfetamine—Vomiting—Capecitabine—stomach cancer	0.00122	0.00136	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—stomach cancer	0.00121	0.00135	CcSEcCtD
Lisdexamfetamine—Rash—Capecitabine—stomach cancer	0.00121	0.00135	CcSEcCtD
Lisdexamfetamine—Insomnia—Epirubicin—stomach cancer	0.00121	0.00135	CcSEcCtD
Lisdexamfetamine—Dermatitis—Capecitabine—stomach cancer	0.00121	0.00135	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—stomach cancer	0.0012	0.00135	CcSEcCtD
Lisdexamfetamine—Headache—Capecitabine—stomach cancer	0.0012	0.00134	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—stomach cancer	0.0012	0.00134	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—stomach cancer	0.00119	0.00133	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Epirubicin—stomach cancer	0.00119	0.00133	CcSEcCtD
Lisdexamfetamine—Somnolence—Epirubicin—stomach cancer	0.00119	0.00133	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—stomach cancer	0.00118	0.00132	CcSEcCtD
Lisdexamfetamine—Nausea—Docetaxel—stomach cancer	0.00117	0.00131	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Epirubicin—stomach cancer	0.00117	0.00131	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Epirubicin—stomach cancer	0.00116	0.0013	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Epirubicin—stomach cancer	0.00115	0.00129	CcSEcCtD
Lisdexamfetamine—Fatigue—Epirubicin—stomach cancer	0.00115	0.00129	CcSEcCtD
Lisdexamfetamine—Constipation—Epirubicin—stomach cancer	0.00114	0.00128	CcSEcCtD
Lisdexamfetamine—Nausea—Capecitabine—stomach cancer	0.00114	0.00127	CcSEcCtD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—HTR1A—stomach cancer	0.00113	0.0162	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Methotrexate—stomach cancer	0.00113	0.00127	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—stomach cancer	0.00113	0.00126	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—stomach cancer	0.00112	0.00125	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—BLVRB—stomach cancer	0.00111	0.0158	CbGpPWpGaD
Lisdexamfetamine—Dyspnoea—Doxorubicin—stomach cancer	0.0011	0.00123	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—stomach cancer	0.0011	0.00123	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—stomach cancer	0.00109	0.00122	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Doxorubicin—stomach cancer	0.00107	0.0012	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.00107	0.00119	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—stomach cancer	0.00106	0.00119	CcSEcCtD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRB1—stomach cancer	0.00106	0.0152	CbGpPWpGaD
Lisdexamfetamine—Urticaria—Epirubicin—stomach cancer	0.00106	0.00119	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—stomach cancer	0.00106	0.00118	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Epirubicin—stomach cancer	0.00105	0.00118	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—stomach cancer	0.00105	0.00117	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PRKAB1—stomach cancer	0.00104	0.0148	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Methotrexate—stomach cancer	0.00102	0.00114	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Epirubicin—stomach cancer	0.000983	0.0011	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—stomach cancer	0.000981	0.0011	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—BLVRB—stomach cancer	0.000979	0.014	CbGpPWpGaD
Lisdexamfetamine—Body temperature increased—Doxorubicin—stomach cancer	0.000976	0.00109	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—stomach cancer	0.000975	0.00109	CcSEcCtD
Lisdexamfetamine—Asthenia—Epirubicin—stomach cancer	0.000957	0.00107	CcSEcCtD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—HTR1A—stomach cancer	0.000953	0.0136	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Methotrexate—stomach cancer	0.000943	0.00105	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Epirubicin—stomach cancer	0.000913	0.00102	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—stomach cancer	0.00091	0.00102	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—stomach cancer	0.000906	0.00101	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—stomach cancer	0.000899	0.00101	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—stomach cancer	0.000898	0.001	CcSEcCtD
Lisdexamfetamine—SLC6A3—Alpha-synuclein signaling—FYN—stomach cancer	0.000896	0.0128	CbGpPWpGaD
Lisdexamfetamine—Headache—Methotrexate—stomach cancer	0.000893	0.000999	CcSEcCtD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRB1—stomach cancer	0.000891	0.0128	CbGpPWpGaD
Lisdexamfetamine—Asthenia—Doxorubicin—stomach cancer	0.000886	0.00099	CcSEcCtD
Lisdexamfetamine—Dizziness—Epirubicin—stomach cancer	0.000882	0.000986	CcSEcCtD
Lisdexamfetamine—ADRA1B—Monoamine GPCRs—ADRB2—stomach cancer	0.000859	0.0123	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Epirubicin—stomach cancer	0.000848	0.000949	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—stomach cancer	0.000847	0.000947	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Doxorubicin—stomach cancer	0.000845	0.000944	CcSEcCtD
Lisdexamfetamine—Rash—Epirubicin—stomach cancer	0.000841	0.000941	CcSEcCtD
Lisdexamfetamine—Dermatitis—Epirubicin—stomach cancer	0.00084	0.00094	CcSEcCtD
Lisdexamfetamine—Headache—Epirubicin—stomach cancer	0.000836	0.000935	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—SLC1A2—stomach cancer	0.000823	0.0118	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Doxorubicin—stomach cancer	0.000816	0.000913	CcSEcCtD
Lisdexamfetamine—Nausea—Epirubicin—stomach cancer	0.000793	0.000886	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PRKAA1—stomach cancer	0.000786	0.0113	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Doxorubicin—stomach cancer	0.000785	0.000878	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—CLCN3—stomach cancer	0.000779	0.0112	CbGpPWpGaD
Lisdexamfetamine—Rash—Doxorubicin—stomach cancer	0.000778	0.00087	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—stomach cancer	0.000778	0.00087	CcSEcCtD
Lisdexamfetamine—Headache—Doxorubicin—stomach cancer	0.000773	0.000865	CcSEcCtD
Lisdexamfetamine—Nausea—Doxorubicin—stomach cancer	0.000733	0.00082	CcSEcCtD
Lisdexamfetamine—ADRA1B—Amine ligand-binding receptors—ADRB2—stomach cancer	0.000722	0.0103	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—KISS1R—stomach cancer	0.0007	0.01	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—STAT3—stomach cancer	0.000693	0.00993	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC1A2—stomach cancer	0.000667	0.00956	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—SLC1A2—stomach cancer	0.000631	0.00903	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1R—stomach cancer	0.000626	0.00896	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HBEGF—stomach cancer	0.000548	0.00785	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—IL1B—stomach cancer	0.000529	0.00757	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—CLCN3—stomach cancer	0.000524	0.00751	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—TGFA—stomach cancer	0.000515	0.00738	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SERPINA1—stomach cancer	0.000508	0.00727	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HSPA8—stomach cancer	0.000492	0.00704	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—SLC1A2—stomach cancer	0.000491	0.00703	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—IL1B—stomach cancer	0.000468	0.00671	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—RGS2—stomach cancer	0.000465	0.00666	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—CLCN3—stomach cancer	0.000464	0.00665	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—CYP2A6—stomach cancer	0.000464	0.00665	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—KISS1R—stomach cancer	0.000464	0.00664	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—TGFA—stomach cancer	0.000456	0.00654	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—KISS1—stomach cancer	0.000451	0.00646	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SERPINA1—stomach cancer	0.00045	0.00644	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC1A2—stomach cancer	0.000449	0.00643	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—stomach cancer	0.000413	0.00592	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—CYP2A6—stomach cancer	0.000411	0.00589	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KISS1—stomach cancer	0.000403	0.00578	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC1A2—stomach cancer	0.000398	0.0057	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—RGS2—stomach cancer	0.000388	0.00555	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—GAST—stomach cancer	0.000388	0.00555	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TNF—stomach cancer	0.000384	0.00549	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HSPA8—stomach cancer	0.000377	0.0054	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—SLC1A2—stomach cancer	0.000376	0.00538	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HBEGF—stomach cancer	0.000367	0.00526	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—KISS1R—stomach cancer	0.000353	0.00505	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—stomach cancer	0.000347	0.00497	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RGS2—stomach cancer	0.000347	0.00497	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TNF—stomach cancer	0.00034	0.00487	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC1A2—stomach cancer	0.000339	0.00486	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HRH4—stomach cancer	0.000335	0.0048	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTP1—stomach cancer	0.000326	0.00466	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HBEGF—stomach cancer	0.000325	0.00466	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—HMOX1—stomach cancer	0.000321	0.0046	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB1—stomach cancer	0.000317	0.00455	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTM1—stomach cancer	0.000299	0.00428	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—KISS1—stomach cancer	0.000299	0.00428	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP2—stomach cancer	0.000294	0.00421	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HSPA8—stomach cancer	0.000293	0.0042	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—F2R—stomach cancer	0.000291	0.00416	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTP1—stomach cancer	0.000288	0.00413	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—HMOX1—stomach cancer	0.000284	0.00407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—RHOA—stomach cancer	0.000278	0.00398	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—ANXA1—stomach cancer	0.000273	0.00391	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—PRKCB—stomach cancer	0.000268	0.00384	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTM1—stomach cancer	0.000265	0.0038	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—F2R—stomach cancer	0.00026	0.00372	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ADRB2—stomach cancer	0.000257	0.00368	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HRH4—stomach cancer	0.000255	0.00365	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—RHOA—stomach cancer	0.000245	0.00351	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—stomach cancer	0.000244	0.0035	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—CXCL8—stomach cancer	0.000244	0.0035	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC1A2—stomach cancer	0.000228	0.00327	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—KISS1—stomach cancer	0.000227	0.00326	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—AGTR2—stomach cancer	0.000227	0.00325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—JUN—stomach cancer	0.000227	0.00325	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—F2R—stomach cancer	0.000225	0.00322	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HSPA8—stomach cancer	0.000225	0.00322	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—MMP9—stomach cancer	0.000221	0.00316	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR1A—stomach cancer	0.000219	0.00313	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HBEGF—stomach cancer	0.000208	0.00298	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—CDKN1A—stomach cancer	0.000207	0.00297	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—PRKCB—stomach cancer	0.000206	0.00294	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB1—stomach cancer	0.000205	0.00293	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC1A2—stomach cancer	0.000202	0.00289	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—KISS1R—stomach cancer	0.000199	0.00286	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—AGTR2—stomach cancer	0.000195	0.00279	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—F2R—stomach cancer	0.000192	0.00276	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR1A—stomach cancer	0.000187	0.00268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KISS1R—stomach cancer	0.000181	0.00259	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ANXA1—stomach cancer	0.000181	0.00259	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—ALB—stomach cancer	0.000181	0.00259	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—EGFR—stomach cancer	0.000178	0.00256	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—PRKCB—stomach cancer	0.000176	0.00252	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB1—stomach cancer	0.000175	0.00251	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—ADRB2—stomach cancer	0.000166	0.00237	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—PRKCB—stomach cancer	0.00016	0.00229	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—HMOX1—stomach cancer	0.000153	0.00219	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—AGTR2—stomach cancer	0.000148	0.00212	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—F2R—stomach cancer	0.000147	0.0021	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—stomach cancer	0.000146	0.00209	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HRH4—stomach cancer	0.000144	0.00207	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—HRAS—stomach cancer	0.000143	0.00205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—HTR1A—stomach cancer	0.000143	0.00204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—stomach cancer	0.000142	0.00203	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—stomach cancer	0.000141	0.00202	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—stomach cancer	0.000138	0.00198	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ANXA1—stomach cancer	0.000138	0.00197	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—stomach cancer	0.000136	0.00195	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRB1—stomach cancer	0.000133	0.00191	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRH4—stomach cancer	0.000131	0.00188	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—stomach cancer	0.000131	0.00187	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—KISS1—stomach cancer	0.000129	0.00184	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—PRKCB—stomach cancer	0.000123	0.00175	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—ALB—stomach cancer	0.000122	0.00174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—stomach cancer	0.000117	0.00167	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KISS1—stomach cancer	0.000117	0.00167	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—APOA1—stomach cancer	0.000116	0.00166	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—HRAS—stomach cancer	0.000111	0.00159	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RGS2—stomach cancer	0.000111	0.00158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—GAST—stomach cancer	0.000111	0.00158	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ADRB2—stomach cancer	0.000108	0.00155	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—ALB—stomach cancer	0.000108	0.00154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KISS1R—stomach cancer	0.000107	0.00153	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GLI3—stomach cancer	0.000107	0.00153	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MAPK1—stomach cancer	0.000106	0.00152	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—stomach cancer	0.000103	0.00147	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RBP1—stomach cancer	0.000102	0.00146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RGS2—stomach cancer	0.0001	0.00144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—GAST—stomach cancer	0.0001	0.00144	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ALB—stomach cancer	9.18e-05	0.00131	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—stomach cancer	9.11e-05	0.0013	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—HRAS—stomach cancer	8.5e-05	0.00122	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AGTR2—stomach cancer	8.38e-05	0.0012	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WWOX—stomach cancer	8.32e-05	0.00119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—F2R—stomach cancer	8.28e-05	0.00119	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—stomach cancer	8.24e-05	0.00118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—HTR1A—stomach cancer	8.06e-05	0.00115	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—APOA1—stomach cancer	7.79e-05	0.00112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ANXA1—stomach cancer	7.79e-05	0.00112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRH4—stomach cancer	7.74e-05	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—WIF1—stomach cancer	7.74e-05	0.00111	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AGTR2—stomach cancer	7.61e-05	0.00109	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB1—stomach cancer	7.54e-05	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—F2R—stomach cancer	7.52e-05	0.00108	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HTR1A—stomach cancer	7.32e-05	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKAB1—stomach cancer	7.14e-05	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—stomach cancer	7.12e-05	0.00102	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ANXA1—stomach cancer	7.07e-05	0.00101	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—APOA1—stomach cancer	6.9e-05	0.000989	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KISS1—stomach cancer	6.9e-05	0.000987	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RNF43—stomach cancer	6.9e-05	0.000987	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL8—stomach cancer	6.86e-05	0.000982	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB1—stomach cancer	6.85e-05	0.000981	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—stomach cancer	6.77e-05	0.00097	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—stomach cancer	6.77e-05	0.000969	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—stomach cancer	6.61e-05	0.000947	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—stomach cancer	6.57e-05	0.000941	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—stomach cancer	6.4e-05	0.000916	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MAPK1—stomach cancer	6.31e-05	0.000904	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ALB—stomach cancer	6.17e-05	0.000884	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FST—stomach cancer	6.15e-05	0.00088	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ADRB2—stomach cancer	6.11e-05	0.000875	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HBEGF—stomach cancer	6.01e-05	0.000861	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GAST—stomach cancer	5.93e-05	0.000849	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RGS2—stomach cancer	5.93e-05	0.000849	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—stomach cancer	5.88e-05	0.000841	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGG—stomach cancer	5.62e-05	0.000805	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ADRB2—stomach cancer	5.55e-05	0.000795	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ALB—stomach cancer	5.47e-05	0.000783	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PPP2R1A—stomach cancer	5.44e-05	0.000779	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—stomach cancer	5.44e-05	0.000778	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKAA1—stomach cancer	5.41e-05	0.000775	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RBP4—stomach cancer	5.23e-05	0.000748	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—CXCL8—stomach cancer	5.22e-05	0.000748	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—stomach cancer	5.2e-05	0.000745	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—HRAS—stomach cancer	5.07e-05	0.000726	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSPB1—stomach cancer	4.49e-05	0.000644	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AGTR2—stomach cancer	4.49e-05	0.000644	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BMP2—stomach cancer	4.44e-05	0.000636	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—F2R—stomach cancer	4.44e-05	0.000636	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKR1C3—stomach cancer	4.37e-05	0.000626	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HTR1A—stomach cancer	4.33e-05	0.000619	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PRKCB—stomach cancer	4.19e-05	0.0006	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ANXA1—stomach cancer	4.18e-05	0.000598	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB1—stomach cancer	4.05e-05	0.000579	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RPS6—stomach cancer	3.87e-05	0.000554	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PRKCB—stomach cancer	3.8e-05	0.000545	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6ST—stomach cancer	3.79e-05	0.000543	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HBEGF—stomach cancer	3.55e-05	0.000509	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6R—stomach cancer	3.38e-05	0.000484	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—RHOA—stomach cancer	3.36e-05	0.000481	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ADRB2—stomach cancer	3.28e-05	0.000469	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PPP2R1A—stomach cancer	3.21e-05	0.00046	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RHOA—stomach cancer	3.05e-05	0.000437	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SMAD4—stomach cancer	2.98e-05	0.000427	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—CXCL8—stomach cancer	2.95e-05	0.000423	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FYN—stomach cancer	2.83e-05	0.000406	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—CXCL8—stomach cancer	2.68e-05	0.000384	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FGFR2—stomach cancer	2.66e-05	0.000381	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IRS2—stomach cancer	2.43e-05	0.000349	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CAV1—stomach cancer	2.36e-05	0.000338	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APOA1—stomach cancer	2.36e-05	0.000337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PRKCB—stomach cancer	2.25e-05	0.000322	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6ST—stomach cancer	2.24e-05	0.00032	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—stomach cancer	2.15e-05	0.000308	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK3—stomach cancer	2.06e-05	0.000295	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6R—stomach cancer	2e-05	0.000286	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK1—stomach cancer	1.96e-05	0.000281	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—EGFR—stomach cancer	1.96e-05	0.000281	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—stomach cancer	1.87e-05	0.000268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SERPINE1—stomach cancer	1.87e-05	0.000268	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—stomach cancer	1.85e-05	0.000265	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RHOA—stomach cancer	1.8e-05	0.000258	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—NOS3—stomach cancer	1.78e-05	0.000256	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—stomach cancer	1.7e-05	0.000243	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—stomach cancer	1.67e-05	0.000239	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CXCL8—stomach cancer	1.58e-05	0.000227	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—HRAS—stomach cancer	1.57e-05	0.000225	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—stomach cancer	1.55e-05	0.000221	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL6—stomach cancer	1.51e-05	0.000216	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—stomach cancer	1.48e-05	0.000211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUN—stomach cancer	1.47e-05	0.000211	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MMP9—stomach cancer	1.43e-05	0.000205	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1A—stomach cancer	1.43e-05	0.000204	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK8—stomach cancer	1.39e-05	0.000199	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—stomach cancer	1.29e-05	0.000184	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—STAT3—stomach cancer	1.27e-05	0.000182	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK3—stomach cancer	1.22e-05	0.000174	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—stomach cancer	1.18e-05	0.000169	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK1—stomach cancer	1.16e-05	0.000166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EGFR—stomach cancer	1.16e-05	0.000166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—stomach cancer	1.09e-05	0.000157	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—stomach cancer	1e-05	0.000144	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—stomach cancer	9.72e-06	0.000139	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HRAS—stomach cancer	9.29e-06	0.000133	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL6—stomach cancer	8.89e-06	0.000127	CbGpPWpGaD
